gurufocus.comOct 13$JNJ

Johnson & Johnson (JNJ) Raises 2026 Sales and EPS Guidance After

Johnson & Johnson (JNJ) reported Q3 non-GAAP EPS of $2.59, beating estimates by $0.06. The company raised its 2026 sales forecast to $101.2B and adjusted EPS guidance to $11.10. Shares gained 1% in after-hours trading. JNJ offers a 1.95% dividend yield with a 55% payout ratio and a 4.9% 3-year dividend growth rate. The company's GF Score™ is 83/100, reflecting strong financial health and growth prospects. Insider activity shows significant net selling over the past 12 months.

Original reporting

gurufocus.com

Published Oct 13, 2026, 11:57 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Oct 13, 2026, 12:24 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefEarnings

Primary signal

$JNJ

Bullish

high confidence

Mentioned

$JNJ

Relevance

9/10

AlphAI data visualization · based on gurufocus.com

Decision brief

The 30-second read

$JNJBullishHigh

Why it matters

Guidance lift could attract income investors and boost dividend‑oriented ETFs.

Market read

First‑report earnings and guidance update for a mega‑cap health stock, likely to move the ticker and related sector funds.

What to watch

Insider net selling and mixed guru sentiment could temper enthusiasm.

Relevance 9/10Novelty 9/10Timing: after‑hours today

Background

Johnson & Johnson reported Q3 results, beating EPS expectations and raising full‑year guidance.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$JNJBullishHigh confidence

Context

Q3 non‑GAAP EPS beat and 2026 sales/adjusted EPS guidance raised, driving a 1% after‑hours price gain.

Expected impact

upward pressure as investors price in higher sales and EPS forecasts

Evidence & confidence

Earnings beat and guidance raise are fresh, material data for a large‑cap health stock.

Market effects

Sector

May lift broader healthcare and dividend‑focused funds as JNJ signals stronger demand.

Regional

U.S. market sentiment could improve modestly in early trading.

Global

Reinforces confidence in global pharma demand, but limited outside U.S. equities.

Counterpoint

What could challenge this read

Valuation remains premium; investors may wait for price correction before buying.

Key entities

company
Johnson & Johnson
Global healthcare conglomerate (ticker JNJ).

Read at source ← All news

$ZBHHighAI 9/10

Zimmer Biomet Soars 15% as Hip and Tech Growth Lifts Guidance, “Validating the Progress” of Its Strategy

Zimmer Biomet (ZBH) shares rose 15% after Q3 sales grew 3.7% in constant currency, with hips, sports medicine, and technology segments growing 7% or more. The company raised its 2026 guidance, citing progress in diversification. Knees, 37% of sales, declined 2.6%. Rival Stryker (SYK) and Smith & Nephew (SNN) also saw gains, despite Smith & Nephew cutting its outlook.

finance.yahoo.comNov 4

$JNJMedAI 8/10

Johnson & Johnson’s Javelin Catheter Met Both Trial Goals and Its Impella Data Pushed Back on a Negative Study. Here’s What It Doesn’t Settle

Johnson & Johnson (JNJ) reported positive results for its Javelin catheter, meeting both primary goals in a pivotal study. Impella heart pump data showed lower death rates than a previous negative study. Javelin is still under FDA review, and Impella's recovery depends on future trials. JNJ's cardiovascular unit saw a sales decline, with Impella contributing 1.6% of total revenue. Analysts project a ~25% total return for JNJ stock.

finance.yahoo.comNov 2

$JNJMed

TREMFYA® (guselkumab) reimbursed for the treatment of moderately to severely active Crohn’s disease and ulcerative colitis for use in Ireland

Johnson & Johnson's TREMFYA (guselkumab) has been approved for reimbursement in Ireland for treating moderately to severely active Crohn’s disease and ulcerative colitis. The approval is based on Phase 3 trials showing significant clinical remission rates. According to the company, it offers a novel dual mechanism of action and improved outcomes for patients.

imt.ieNov 2

$JNJMed

J&J data show lower mortality with Impella in HRPCI than CHIP-BCIS3

Johnson & Johnson (J&J) presented data at a symposium showing lower mortality rates in high-risk PCI patients using Impella heart pumps compared to the CHIP-BCIS3 trial. Three analyses, involving 1,379 patients, reported 30-day mortality rates of 6.1% and 4.7%, and 90-day rates of 6.5%. J&J's heart recovery chief medical officer highlighted the importance of device usage and patient selection. The company continues studying Impella, with PROTECT IV trial results expected in 2027.

medicaldevice-network.comNov 2

$JNJMedAI 8/10

J&J's Javelin Meets Pivotal Coronary Study Goals; Highlights Impella Survival Data At TCT

Johnson & Johnson (JNJ) reported that its Shockwave Javelin coronary catheter met primary endpoints in the FORWARD CAD study, with 93.6% successful lesion crossing and 93.4% safety. The study involved 158 patients. Separately, J&J shared favorable Impella data from three analyses, showing low mortality rates. JNJ closed at $273.20, down 0.73%.

rttnews.comNov 2

$JNJHigh

PROTEUS: Perioperative Apalutamide Plus ADT Improves EFS in High-Risk Locally Advanced Prostate Cancer

A substudy of the phase 3 PROTEUS trial, presented at ESMO Congress 2026, showed that perioperative apalutamide plus ADT reduced recurrence or death risk by 62% in high-risk prostate cancer patients. The study, supported by Johnson & Johnson, met primary endpoints, including event-free survival and metastasis-free survival. Lead author Alberto Briganti suggested the treatment could become a standard option for eligible patients.

endocrinologyadvisor.comNov 2